Shop
eStoreRx™
Online Supplement Dispensary
eStoreRx™ is an easy direct-to-patient ordering & fulfilment program for lifelong wellness.
For over 40 years, Biotics Research Corporation has revolutionized the nutritional supplement industry by utilizing “The Best of Science and Nature”. Combining nature’s principles with scientific ingenuity, our products magnify the nutritional
eStoreRx™ is an easy direct-to-patient ordering & fulfilment program for lifelong wellness.
November 14 2024
Exciting research is being done in the burgeoning field called Metabolic Psychiatry, which is dedicated to addressing the bioenergetic underpinnings o...
The American Journal of Clinical Nutrition recently published a secondary analysis of a randomized and controlled 2x2 factorial trial, revealing a reduction in colorectal polyp formation with EPA ( eicosapentaenoic acid) supplementation when stratified by genotype. Initial results of this study were reported in the Lancet in 2018, in which neither aspirin nor EPA reduced the risk for polyp formation among people considered at high-risk, but these early results did not include a genetic analysis.
A component of the STOP-ADENOMA study, the seAFOod polyp prevention trial enrolled participants in the English Bowel Cancer Screening Programme aged 55-73 deemed at high risk, i.e., at baseline they had an increase in the size and/or number of adenomas. Over 700 participants received either placebo, 300mg aspirin per day, 2g EPA per day, or both aspirin and EPA for 12 months. In the Lancet article, neither treatment reduced the primary outcome, the adenoma detection rate (ADR, the proportion of participants with any adenoma). This is in contrast to the chemopreventative efficacy EPA has shown for familial adenomatous polyposis.
However, this more recent publication was stratified by one specific polymorphism in the fatty acid desaturase (FADS) gene, rs66698963, previously shown to influence levels of arachidonic acid (AA). An insertion-deletion polymorphism, AA levels have been observed to be as much as 50% greater among people who are insertion homozygotes compared to deletion homozygotes. In this trial, EPA supplementation among people with at least one insertion allele reduced the incidence rate of adenomas by 50%. No benefit was observed among people without the insertion allele, and no difference was observed when aspirin use was stratified by genotype. Several hypotheses exist for the gene-nutrient interaction observed with EPA, including competition with AA as a substrate for cyclooxygenase (COX), or otherwise interferes with FADS1 expression, thereby inhibiting the production of pro-inflammatory tumorigenic signals.
Submit this form and you'll receive our latest news and updates.
*These statements have not been evaluated by the Food and Drug Administration. This product has not intended to diagnose, treat, cure, or prevent any disease.
© 2023 Biotics Research Corporation - All Rights Reserved
Submit your comment